Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: Are older strategies more cost-effective in the general population?

Rheumatology

Volumn 45, Issue 5, 2006, Pages 606-613

  Elliott, Rachel A ^a   Hooper, L ^a   Payne, K ^a   Brown, T J ^a   Roberts, C ^a   Symmons, D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

COX 2 specific inhibitors; Drug utilization; Gastrointestinal events; Health economics; Health resource utilization; NSAIDs; Outcomes; Preventive strategies

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MELOXICAM; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; VALDECOXIB;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; MALE; MEDICAL DECISION MAKING; META ANALYSIS; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; STOMACH PROTECTION; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; DECISION SUPPORT TECHNIQUES; GASTROINTESTINAL DISEASES; GREAT BRITAIN; HEALTH CARE COSTS; HISTAMINE H2 ANTAGONISTS; HUMANS; MISOPROSTOL; QUALITY-ADJUSTED LIFE YEARS;

EID: 33646199502     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei241     Document Type: Article

References (42)

1. Blower AL, Brooks A, Fenn GC et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Therap 1997;11:283-91.
2. Hooper L, Brown TJ, Elliott RA, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: Systematic review. Br Med J 2004;329:948-52.
3. Spiegel BMR, Chiou C-F, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: Cost effectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005;53:185-97.
4. Goldstein JL. Yet another model looking at the cost effectiveness of COX-2 selective inhibitors. Evidence-based Gastroenterol 2003; 4:133-4.
5. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998;41:16-25.
6. Moore RA, Phillips CJ, Pellissier JM, Kong SX. Health economic comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. J Med Econ 2001;4:1-17.
7. National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam, and etodolac for osteoarthritis and rheumatoid arthritis, Technology Appraisal Guidance 27. London, NICE, 2001.
8. Department of Health. Prescription cost analysis 2000. DoH national statistics, 2004 (http://www.dh.gov.uk/assetRoot/04/10/76/26/ 04107626.pdf).
9. MacDonald TM, Morant SV, Robinson GC et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study. Br Med J 1997; 315:1333-7.
10. Rodriguez LAG, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists and other antihypertensive drugs. Arch Intern Med 1998;158:33-9.
11. Henry D, Lim L, Rodriguez LAG et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br Med J 1996;312:1563-6.
12. Hernandez-Diaz S, Rodriguez LAG. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation. Arch Intern Med 2000;160:2093-9.
13. WHO Collaborating Centre for Drug Statistics Methodology. Complete ATC index 2003 (www.whocc.no/atcdd).
14. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
15. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthriAis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000;284:1247-55.
16. White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus non-steroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Therap 2004; 11:244-50.
17. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
18. Hankey GJ, Eikelboom JW. Cyclooxygenase-2 inhibitors: Are they really atherothrombotic, and if not, why not? Stroke 2003; 34:2736-40.
19. Bogaty P, Brophy JM, Noel M et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: A randomized placebo-controlled study. Circulation 2004; 110:934-9.
20. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin and cardiovascular disease. Arthritis Rheum 2003;48:12-20.
21. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxgenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population-based nested case-control analysis. Br Med J 2005;330:1366-72.
22. Taha AS, Dahill S, Sturrock RD, Lee FD, Russell RI. Predicting NSAID related ulcers: Assessment of clinical and pathological risk factors and importance of differences in NSAID. Gut 1994; 35:891-5.
23. Kubba AK, Whyman MR. Upper gastro-intestinal disease in Scotland: A survey of practice amongst Scottish gastroenterologists. J R Coll Surg Edin 1996;41:302-6.
24. Ming-Yu L, Hsien-Hong L, Pang-Chi C. Duodenal ulcer haemorrhage with or without dyspepsia. Am J Gastroenterol 1990; 85:1343-5.
25. Peris F, Martinez E, Badia X, Brosa M. Iatrogenic cost factors incorporating mild and moderate adverse effects in the economic comparison of aceclofenac and other NSAIDs. Pharmacoeconomics 2001;19:779-90.
26. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary, 45th edn. London: Pharmaceutical Press, 2003.
27. ®ISK: Risk analysis and simulation add-in for Microsoft Excel, version 4.5. New York: Palisade Corporation, 2002.
28. Fendick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost effectiveness acceptability curves. Health Econ 2001;10:779-87.
29. Song F, Altman D, Glenny A, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. Br Med J 2003;326:472-5.
30. National Prescribing Centre. Vioxx (rofecoxib) withdrawal. MeReC EXTRA 15. Liverpool: National Prescribing Centre, 2004.
31. Sturkenboom MCJM, Burke TA, Dieleman JP, Tangelder MJD, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving non-steroidal anti-inflammatory drugs. Rheumatology 2003;42:iIi23-iii31.
32. Sturkenboom MCJM, Burke TA, Tangelder MJD, Dieleman JP, Walton S, Goldstein JL. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Therap 2003;18:1137-47.
33. Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: Implications for the cost effectiveness of Cyclo-oxygenase 2 inhibitors (COX-2s). Am J Manag Care 2003;9:785-94.
34. Groeneveld PW, Lieu TA, Fendrick AM et al. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol 2001;96:338-47.
35. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: A cost-utility study. J Fam Pract 1997;44:545-55.
36. Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol 1997;92:614-20.
37. National Health Service England and Wales. Drug tariff, July edn. London: The Stationery Office, 2003.
38. British Society of Gastroenterology Endoscopy Committee. Non-variceal upper gastrointestiVal haemorrhage: Guidelines. Gut 2002;51:iv1-iv6.
39. Netten A, Curtis L. Unit costs of health and social care 2002. Canterbury: PSSRU, 2003.
40. National Health Service Executive. NHS reference costs 2002 (http://www.dh.gov.uk/PublicationsandStatistics/Publications/ PublicationspolicyandGuidancearticle/fs/ en?CONTENTID=4069646&chk=kk52).
41. Heyland D, Gafni A, Griffith L et al. The clinical and economic consequences of clinically important gastro-intestinal bleeding in critically ill patients. Clin Intens Care 1996;7:121-5.
42. Gralnek IM, Jensen DM, Gornbein J et al. Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: An analysis of two prospective clinical trials. Am J Gastroenterol 1998;93:2047-56.